30 patents
Utility
Cytotoxic and Anti-mitotic Compounds, and Methods of Using the Same
7 Dec 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. WINTERS, Alexander Laurence MANDEL, James R. RICH, Bradley John HEDBERG, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, John BABCOOK
Filed: 21 Feb 23
Utility
Cytotoxic and Anti-mitotic Compounds, and Methods of Using the Same
5 Oct 23
Compounds having cytotoxic and/or anti-mitotic activity are disclosed.
Geoffrey C. WINTERS, James R. RICH, Graham Albert Edwin GARNETT, Alexander Laurence MANDEL, Tom Han Hsiao HSIEH, Elyse Marie Josée BOURQUE, Stuart Daniel BARNSCHER
Filed: 20 Jan 23
Utility
IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS
28 Sep 23
Fc variants are described comprising one or more amino acid mutations that increase the stability of the Fc variant as compared to a parental Fc that does not include the one or more amino acid mutations, as well as polypeptides comprising an Fc variant and polynucleotides encoding an Fc variant.
Genevieve DESJARDINS, Eric ESCOBAR-CABRERA, Antonios SAMIOTAKIS, Gavin Carl JONES
Filed: 20 May 21
Utility
Anti-tissue Factor Antibody-drug Conjugates and Related Methods
18 Aug 22
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs.
Jan-Willem Theunissen, Allen G. Cai, Thi-Sau Migone
Filed: 2 Jul 20
Utility
Modified Antigen Binding Polypeptide Constructs and Uses Thereof
11 Aug 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Mario SANCHES, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A.L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
Filed: 25 Feb 22
Utility
Engineered Immunoglobulin Heavy Chain-light Chain Pairs and Uses Thereof
21 Jul 22
The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof.
Adam Louis CORPER, Dunja UROSEV, Stacey A.L. TOM-YEW, Dustin Weyland Blue BLEILE, Thomas SPRETER VON KREUDENSTEIN, Surjit DIXIT, Paula Irene LARIO, Mario SANCHES
Filed: 24 Jan 22
Utility
Methods of Using a Bispecific Antigen-binding Construct Targeting HER2 for the Treatment of Biliary Tract Cancers
5 May 22
Described herein is a method of treating biliary tract cancer (BTC) comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) to a subject.
Diana F. Hausman, Neil C. Josephson, Rose Kamyee Lai, Gerald James Rowse, Patrick Kaminker
Filed: 19 Nov 21
Utility
Bispecific Antigen-binding Constructs Targeting HER2
30 Dec 21
Provided herein are biparatopic antigen-binding constructs that specifically bind HER2.
Nina E. Weisser, Gordon Yiu Kon NG, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Filed: 24 Feb 21
Utility
Antigen-Binding Constructs Targeting HER2
23 Dec 21
Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2.
Eric Escobar-Cabrera, Leonard G. Presta
Filed: 3 May 21
Utility
ANTI-PD-1/LAG3 Bispecific Antibodies
2 Dec 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
Filed: 23 Jul 21
Utility
ANTI-PD-1/LAG3 Bispecific Antibodies
25 Nov 21
Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments.
Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
Filed: 23 Jul 21
Utility
Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof
18 Nov 21
Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain.
Dunja UROSEV, Stacey A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
Filed: 27 Apr 21
Utility
ANTI-HER2 Biparatopic Antibody-drug Conjugates and Methods of Use
11 Nov 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K.C. Fung, Stuart D. Barnscher
Filed: 23 Mar 21
Utility
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
14 Oct 21
Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells.
Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter von Kreudenstein, Nina E. Weisser
Filed: 19 Mar 21
Utility
Engineered Immunoglobulin Heavy Chain-Light Chain Pairs and Uses Thereof
7 Oct 21
Provided are heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain.
Adam Louis Corper, Dunja Urosev, Stacey A.L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
Filed: 9 Jun 21
Utility
STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN
9 Sep 21
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g.
Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon, Igor D'Angelo
Filed: 30 Nov 20
Utility
Methods Using Monovalent Antigen Binding Constructs Targeting HER2
2 Sep 21
Provided herein are methods of use and treatment using a first or a first and second monovalent antigen-binding constructs targeting HER2.
Gordon Yiu Kon NG, Nina E. WEISSER, Grant Raymond WICKMAN
Filed: 17 Dec 20
Utility
ANTI-HER2 Biparatopic Antibody-drug Conjugates and Methods of Use
26 Aug 21
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer.
Kevin HAMBLETT, Rupert H. DAVIES, James R. RICH, Gerald J. ROWSE, Vincent K.C. FUNG, Stuart D. BARNSCHER
Filed: 12 Mar 19
Utility
Methods of Using Bispecific Antigen-binding Constructs Targeting HER2
24 Jun 21
Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors.
Grant Raymond Wickman, Gordon Yiu Kon Ng, Nina E. Weisser
Filed: 25 Sep 20
Utility
Methods of Using a Bispecific Antigen-binding Construct Targeting HER2 In Combination with CDK4/6 Inhibitors for the Treatment of Breast Cancer
10 Jun 21
Described herein is a method of treating breast cancer comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) in combination with a CDK4/6 inhibitor to a subject.
Nina E. Weisser, Diana F. Hausman, Patrick Kaminker
Filed: 29 May 20